Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Prothena Biosciences Limited patents


Recent patent applications related to Prothena Biosciences Limited. Prothena Biosciences Limited is listed as an Agent/Assignee. Note: Prothena Biosciences Limited may have other listings under different names/spellings. We're not affiliated with Prothena Biosciences Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Prothena Biosciences Limited-related inventors


Antibodies that recognize iapp

The invention provides monoclonal antibody 6b8 and related antibodies. The 6b8 antibody binds to an epitope within residues 3-12 of iapp. ... Prothena Biosciences Limited

Anti-mcam antibodies and associated methods of use

Described herein are anti-mcam antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between mcam and its ligand, a protein comprising a laminin α-4 chain. These anti-mcam antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of mcam-expressing cells into a site of inflammation in the body.. ... Prothena Biosciences Limited

Humanized antibodies that recognize alpha-synuclein

The present application discloses humanized 1h7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of lewy body disease.. ... Prothena Biosciences Limited

Humanized antibodies that recognize alpha-synuclein

The present application discloses humanized 9e4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of lewy body disease.. ... Prothena Biosciences Limited

Antibodies to alpha synuclein

The application identifies novel fragments of alpha-synuclein in patients with lewy body disease (lbd) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. ... Prothena Biosciences Limited

Methods for detecting phosphorylated alpha-synuclein

The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (ps129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. ... Prothena Biosciences Limited

Anti-laminin4 antibodies specific for lg1-3

The invention provides antibodies that specifically bind to the lg1-3 modules of the g domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to mcam. ... Prothena Biosciences Limited

Antibodies recognizing alpha-synuclein

The invention provides monoclonal antibody 5c1 and related antibodies. The 5c1 antibody binds to an epitope within residues 118-126 of α-synuclein. ... Prothena Biosciences Limited

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasus arteritis

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. . ... Prothena Biosciences Limited

Antibodies recognizing medin

The invention provides antibodies that specifically bind to medin. The antibodies have the capacity to bind to monomeric, misfolded, aggregated, fibril or deposited forms of medin. ... Prothena Biosciences Limited

Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasus arteritis

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. . ... Prothena Biosciences Limited

Anti-mcam antibodies and associated methods of use

Described herein are anti-mcam antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between mcam and its ligand, a protein comprising a laminin α-4 chain. These anti-mcam antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of mcam-expressing cells into a site of inflammation in the body.. ... Prothena Biosciences Limited

Anti-mcam antibodies and associated methods of use

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.. ... Prothena Biosciences Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Prothena Biosciences Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Prothena Biosciences Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###